| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.1 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.098 | 0.1 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |